Comprehensive Analysis of Monocarboxylate Transporter 4 (MCT4) expression in breast cancer prognosis and immune infiltration via integrated bioinformatics analysis

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA A Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• How CW, Ong YS, Low SS, et al. How far have we explored fungi to fight cancer? Semin Cancer Biol. 2021;S1044579X21000596. DOI:10.1016/j.semcancer.2021.03.009
   Web of Science ®Google Scholar
• Shin Low S, Pan Y, Ji D, et al. Smartphone-based portable electrochemical biosensing system for detection of circulating microRNA-21 in saliva as a proof-of-concept. Sens Actuators B Chem. 2020;308:127718.
   Web of Science ®Google Scholar
• Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here: checkpoint Inhibitors in TNBC. Cancer. 2018;124(10):2086–2103.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang Y, Wu S, et al. MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered. 2017;8(4):367–373.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59.
   PubMed Web of Science ®Google Scholar
• Reddy SM, Carroll E, Nanda R. Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020;20(3):151–158.
   PubMed Web of Science ®Google Scholar
• Cortés J, André F, Gonçalves A, et al. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol. 2019;15(17):1951–1961.
   PubMed Web of Science ®Google Scholar
• Quintela-Fandino M, Holgado E, Manso L, et al. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res. 2020;22(1):124.
   PubMed Web of Science ®Google Scholar
• Wan M, Zhuang B, Dai X, et al. A new metabolic signature contributes to disease progression and predicts worse survival in melanoma. Bioengineered. 2020;11(1):1099–1111.
   PubMed Web of Science ®Google Scholar
• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.
   PubMed Web of Science ®Google Scholar
• Baltazar F, Afonso J, Costa M, et al. Lactate beyond a waste metabolite: metabolic affairs and signaling in malignancy. Front Oncol. 2020;10:231.
   PubMed Web of Science ®Google Scholar
• Certo M, Tsai C-H, Pucino V, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–161.
   PubMed Web of Science ®Google Scholar
• Poole RC, Halestrap AP. Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol Cell Physiol. 1993;264(4):C761–82.
   Web of Science ®Google Scholar
• Halestrap AP, The MD. SLC16 gene family from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Archiv Eur J Physiol. 2004;447(5):619–628.
   PubMed Web of Science ®Google Scholar
• Sonveaux P, Végran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118:3930–3942. doi:10.1172/JCI36843.
   PubMed Web of Science ®Google Scholar
• Felmlee MA, Jones RS, Rodriguez-Cruz V, et al. Monocarboxylate Transporters (SLC16): function, regulation, and role in health and disease. Pharmacol Rev. 2020;72(2):466–485.
   PubMed Web of Science ®Google Scholar
• Yu S, Wu Y, Li C, et al. Comprehensive analysis of the SLC16A gene family in pancreatic cancer via integrated bioinformatics. Sci Rep. 2020;10(1):7315.
   PubMed Web of Science ®Google Scholar
• Li Z, Wu Q, Sun S, et al. Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targets. Biochem Biophys Res Commun. 2018;501(4):962–967.
   PubMed Web of Science ®Google Scholar
• de Oliveira ATT, Pinheiro C, Longatto-Filho A, et al. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr. 2012;44(1):171–178.
   PubMed Web of Science ®Google Scholar
• Contreras-Baeza Y, Sandoval PY, Alarcón R, et al. Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments. J Biol Chem. 2019;294(52):20135–20147.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.
   PubMed Web of Science ®Google Scholar
• Jézéquel P, Gouraud W, Ben Azzouz F, et al. bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database. 2021;2021:007.
   Google Scholar
• Ringnér M, Fredlund E, Häkkinen J, et al. GOBO: gene expression-based outcome for breast cancer online. PLoS ONE. 2011;6(3):e17911.
   PubMed Web of Science ®Google Scholar
• Á N, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021;11(1):6047.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
   PubMed Web of Science ®Google Scholar
• Baenke F, Dubuis S, Brault C, et al. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival: MCT4 supports breast cancer cell survival. J Pathol. 2015;237(2):152–165.
   PubMed Web of Science ®Google Scholar
• Xiao S, Zhu H, Shi Y, et al. Prognostic and predictive value of monocarboxylate transporter 4 in patients with breast cancer. Oncol Lett. 2020;20(3):2143–2152.
   PubMed Web of Science ®Google Scholar
• Gallagher FA, Woitek R, McLean MA, et al. Imaging breast cancer using hyperpolarized carbon-13 MRI. Proc Natl Acad Sci USA. 2020;117(4):2092–2098.
   PubMed Web of Science ®Google Scholar
• Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and warburg phenomenon. Pharmacol Ther. 2020;206:107451.
   PubMed Web of Science ®Google Scholar
• Choi SYC, Xue H, Wu R, et al. The MCT4 Gene: a novel, potential target for therapy of advanced prostate cancer. Clin Cancer Res. 2016;22(11):2721–2733.
   PubMed Web of Science ®Google Scholar
• Todenhöfer T, Seiler R, Stewart C, et al. Selective inhibition of the lactate transporter MCT4 reduces growth of invasive bladder cancer. Mol Cancer Ther. 2018;17(12):2746–2755.
   PubMed Web of Science ®Google Scholar
• Puri S, Juvale K. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: a review with structure-activity relationship insights. Eur J Med Chem. 2020;199:112393.
   PubMed Web of Science ®Google Scholar
• Long Y, Gao Z, Hu X, et al. Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma. Cancer Med. 2018;7(9):4690–4700.
   PubMed Web of Science ®Google Scholar
• Sun X, Wang M, Wang M, et al. Role of proton-coupled monocarboxylate transporters in cancer: from metabolic crosstalk to therapeutic potential. Front Cell Dev Biol. 2020;8:651.
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Liu J, et al. PKM2, a potential target for regulating cancer. Gene. 2018;668:48–53.
   PubMed Web of Science ®Google Scholar
• Palsson-McDermott EM, Dyck L, Zasłona Z, et al. Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors. Front Immunol. 2017;8:1300.
   PubMed Web of Science ®Google Scholar
• Angiari S, Runtsch MC, Sutton CE, et al. Pharmacological activation of pyruvate kinase M2 Inhibits CD4+ T cell pathogenicity and suppresses autoimmunity. Cell Metab. 2020;31(2):e8.
   PubMed Web of Science ®Google Scholar
• Kudryavtseva AV, Fedorova MS, Zhavoronkov A, et al. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells. BMC Genet. 2016;17(S3):156.
   PubMed Web of Science ®Google Scholar
• Shi T, Ma Y, Cao L, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10(4):308.
   PubMed Web of Science ®Google Scholar
• van Berkel A, Rao JU, Kusters B, et al. Correlation between in Vivo18 F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J Nucl Med. 2014;55(8):1253–1259.
   PubMed Web of Science ®Google Scholar
• Tuo Z, Zheng X, Zong Y, et al. HK3 is correlated with immune infiltrates and predicts response to immunotherapy in non‐small cell lung cancer. Clin Transl Med. 2020;10(1):319–330.
   PubMed Web of Science ®Google Scholar